Spot Ether (ETH) exchange-traded funds experienced $140 million in net outflows on November 2, marking six consecutive days of withdrawals. BlackRock's ETHA fund accounted for the largest outflow at $138 million, though it still holds a cumulative net inflow of $11.731 billion. Meanwhile, Morgan Stanley's Ethereum Trust saw the largest daily inflow of $3.15 million, with total net inflows of $48.24 million. These ETFs collectively hold $13.183 billion in net assets, representing 4.8% of Ether's total market capitalization, indicating sustained investor interest despite recent outflows.
Spot Ether ETFs saw $140 million in net outflows on November 2, continuing a six-day streak of withdrawals. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Nov 03, 2026 13:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell. Notable movers include Balancer (BAL) at Rp16,297 with a 1-day change of +11.14%, EOS.IO (EOS) at Rp12,649 with +8.13%, and Aave (AAVE) at Rp2,276,048 with -5.62% and a Pluang order activity of 74% Sell / 26% Buy.
ZYT officially introduced its Prax Drive System™, a commercial vehicle technology, partnering with leading Chinese truck makers like XCMG, Shacman, and Sinotruk. The system supports heavy trucks, buses, light trucks, and vans, with production underwa...
Yaoyao, the Asia-Pacific growth lead for the Solana Foundation, has announced her departure after three and a half years with the organization. She joined in 2023 and played a key role in expanding Solana's presence in Greater China, including foundi...
On November 2, spot Bitcoin exchange-traded funds (ETFs) experienced net outflows totaling $399 million, primarily driven by Blackrock's IBIT fund which alone lost $405 million. Despite this, Fidelity's FBTC fund recorded the largest inflow of $6.68 ...
The Rose Income Garden portfolio highlights VICI Properties and W. P. Carey as the most undervalued dividend raisers for October, with VICI offering a 7.52% yield and expanding beyond Las Vegas. The portfolio, which includes 69 investments across all...
ARS Pharmaceuticals is rated Buy as its current stock price undervalues its pipeline potential despite commercial challenges. Its main product, neffy, an intranasal epinephrine spray, faces slow market adoption and insurance issues but holds promise ...
